B-cell depletion with rituximab in relapsing-remitting multiple sclerosis

New England Journal of Medicine

Volumn 358, Issue 7, 2008, Pages 676-688

  Hauser, Stephen L ^a   Waubant, Emmanuelle ^a   Arnold, Douglas L ^b,c   Vollmer, Timothy ^d   Antel, Jack ^b   Fox, Robert J ^e   Bar Or, Amit ^b   Panzara, Michael ^f   Sarkar, Neena ^g   Agarwal, Sunil ^g   Langer Gould, Annette ^g   Smith, Craig H ^g  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MCGILL UNIVERSITY   (Canada)

^c NEURORX RESEARCH   (Canada)

^d Barrow Clinic   (United States)

^e LERNER RESEARCH INSTITUTE   (United States)

^f BIOGEN   (United States)

^g GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; GADOLINIUM; GLATIRAMER; INTERFERON BETA SERINE; METHYLPREDNISOLONE; METHYLPREDNISOLONE SODIUM SUCCINATE; NATALIZUMAB; PLACEBO; RITUXIMAB;

ADULT; ARTICLE; B LYMPHOCYTE; BACKACHE; BRAIN DAMAGE; BRONCHITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DEPRESSION; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG FEVER; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; GASTROENTERITIS; HEADACHE; HEAT SENSATION; HUMAN; IMMUNOGENICITY; INFECTION; INFLUENZA; INJECTION SITE REACTION; ISCHEMIC CORONARY ARTERY SYNDROME; LIMB PAIN; LYMPHOCYTE DEPLETION; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PAIN; PHARMACODYNAMICS; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; RELAPSE; REMISSION; RHINOPHARYNGITIS; SIDE EFFECT; SINUSITIS; SORE THROAT; THROAT IRRITATION; THYROID TUMOR; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION;

EID: 39049142995     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa0706383     Document Type: Article

References (37)

1. Hauser SL, Oksenberg JR. The neurobiology of multiple sclerosis: genes, inflammation, and neurodegeneration. Neuron 2006;52:61-76.
2. Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain 1989;112:133-46.
3. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996;39:285-94. [Erratum, Ann Neurol 1996;40:480.]
4. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. Neurology 1995;45:1268-76.
5. Wolinsky JS, Narayana PA, O'Connor P, et al. Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial. Ann Neurol 2007;61:14-24.
6. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354:899-910.
7. Trojano M, Pellegrini F, Fuiani A, et al. New natural history of interferon-beta-treated relapsing multiple sclerosis. Ann Neurol 2007;61:300-6.
8. Owens GP, Bennett JL, Gilden DH, Burgoon MP. The B cell response in multiple sclerosis. Neurol Res 2006;28:236-44.
9. Andersson L, Bolling M, Wirestam R, Holtås S, Ståhlberg F. Combined diffusion weighting and CSF suppression in functional MRI. NMR Biomed 2002;15:235-40.
10. Link H, Huang Y-M. Oligoclonal bands in multiple sclerosis cerebrospinal fluid: an update on methodology and clinical usefulness. J Neuroimmunol 2007;180:17-28.
11. Sidén A. Isoelectric focusing and crossed immunoelectrofocusing of CSF immunoglobulins in MS. J Neurol 1979;221:39-51.
12. Genain CP, Cannella B, Hauser SL, Raine CS. Identification of autoantibodies associated with myelin damage in multiple sclerosis. Nat Med 1999;5:170-5.
13. O'Connor KC, Appel H, Bregoli L, et al. Antibodies from inflamed central nervous system tissue recognize myelin oligodendrocyte glycoprotein. J Immunol 2005;175:1974-82.
14. O'Connor KC, Chitnis T, Griffin DE, et al. Myelin basic protein-reactive autoantibodies in the serum and cerebrospinal fluid of multiple sclerosis patients are characterized by low-affinity interactions. J Neuroimmunol 2003;136:140-8.
15. Kanter JL, Narayana S, Ho PP, et al. Lipid microarrays identify key mediators of autoimmune brain inflammation. Nat Med 2006;12:138-43.
16. Magliozzi R, Howell O, Vora A, et al. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain 2007;130:1089-104.
17. Baranzini SE, Jeong MC, Butunoi C, Murray RS, Bernard CC, Oksenberg JR. B cell repertoire diversity and clonal expansion in multiple sclerosis brain lesions. J Immunol 1999;163:5133-44.
18. Colombo M, Dono M, Gazzola P, et al. Accumulation of clonally related B lymphocytes in the cerebrospinal fluid of multiple sclerosis patients. J Immunol 2000;164:2782-9.
19. Corcione A, Casazza S, Ferretti E, et al. Recapitulation of B cell differentiation in the central nervous system of patients with multiple sclerosis. Proc Natl Acad Sci U S A 2004;101:11064-9.
20. Owens GP, Kraus H, Burgoon MP, Smith-Jensen T, Devlin ME, Gilden DH. Restricted use of VH4 germline segments in an acute multiple sclerosis brain. Ann Neurol 1998;43:236-43.
21. Zhang Y, Da RR, Hilgenberg LG, et al. Clonal expansion of IgA-positive plasma cells and axon-reactive antibodies in MS lesions. J Neuroimmunol 2005;167:120-30.
22. Smith-Jensen T, Burgoon MP, Anthony J, Kraus H, Gilden DH, Owens GP. Comparison of immunoglobulin G heavy-chain sequences in MS and SSPE brains reveals an antigen-driven response. Neurology 2000;54:1227-32.
23. Duddy M, Niino M, Adatia F, et al. Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis. J Immunol 2007;178:6092-9.
24. Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994;83:435-45.
25. Anderson DR, Grillo-López A, Varns C, Chambers KS, Hanna N. Targeted anticancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma. Biochem Soc Trans 1997;25:705-8.
26. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 2000;6:443-6.
27. Duddy M, Bar-Or A. B-cells in multiple sclerosis. Int MS J 2006;13:84-90.
28. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology 1983;33:1444-52.
29. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann Neurol 2001;50:121-7.
30. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Online instructions and guidelines. Bethesda, MD: National Cancer Institute, August 9, 2006. (Accessed January 18, 2008, at http://ctep.cancer.gov/forms/CTCAEv3.pdf.)
31. Bar-Or A, Calabresi P, Arnold D, et al. Rituximab in relapsing remitting multiple sclerosis: a 72-week open-label phase 1 trial. Ann Neurol (in press).
32. Meinl E, Krumbholz M, Hohlfeld R. B lineage cells in the inflammatory central nervous system environment: migration, maintenance, local antibody production, and therapeutic modulation. Ann Neurol 2006;59:880-92.
33. Sell S, Max EE. All about B cells. In: Sell S. Immunology, immunopathology, and immunity. 6th ed. Washington, DC: ASM Press, 2001:101.
34. Breedveld F, Agarwal S, Yin M, et al. Rituximab pharmacokinetics in patients with rheumatoid arthritis: B-cell levels do not correlate with clinical response. J Clin Pharmacol 2007;47:1119-28.
35. Winkler U, Jensen M, Manzke O, Schulz H, Diehl V, Engert A. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood 1999;94:2217-24.
36. Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factory therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006;54:2793-806.
37. FDA public health advisory: life-threatening brain infection in patients with systemic lupus erythematosus after Rituxan (rituximab) treatment. Rockville, MD: Food and Drug Administration, 2006. (Accessed January 18, 2008, at http://www.fda.gov/cder/drug/advisory/rituximab.htm.)